Endpoint choice for inclusion body myositis: a step too far?

The Lancet Neurology

Volume 18, Issue 9, September 2019, Pages 807-808

MG Hanna et al.
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Lancet Neurol
(2019)
K Schmidt et al.
Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment
Curr Opin Rheumatol
(2017)
E Lach-Trifilieff et al.
An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy
Mol Cell Biol
(2014)
AA Amato et al.
Treatment of sporadic inclusion body myositis with bimagrumab
Neurology
(2014)

There are more references available in the full text version of this article.